Giant cell tumor (GCT) of bone is a benign but locally aggressive osteolytic neoplasm that predominantly affects young adults, commonly arising in the meta-epiphyseal regions of long bones. While primarily intraosseous, GCT can exhibit cortical destruction, soft tissue extension, and, in rare instances, pulmonary metastases. Diagnosis is based on characteristic radiographic, CT, and MRI findings, supplemented by histological confirmation of mononuclear stromal cells and osteoclast-like giant cells. Treatment options include intralesional curettage with adjuvants or wide resection, depending on tumor location and aggressiveness. The RANKL inhibitor denosumab has become an important adjunct for tumor downstaging and recurrence control. Despite therapeutic advances, local recurrence remains a concern, necessitating vigilant follow-up.